ClinicalTrials.gg
Active, not recruitingNCT06859788Updated Jul 13, 2026

SPI-1005 for the Treatment of Meniere's Disease (Open Label)

A Phase 3 interventional study of Ebselen in Meniere's Disease and Ménière's Disease, sponsored by Sound Pharmaceuticals, Incorporated. Active, not recruiting at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Sound Pharmaceuticals, Incorporated · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.

02

Conditions studied

  • Meniere's Disease
  • Ménière's Disease

Keywords

  • ebselen
  • hearing loss
  • tinnitus
  • vertigo
  • dizziness
  • SPI-1005
03

In context

Meniere Disease

74 studies on the registry are indexed under Meniere Disease; 12 are open to participants now.

This study's planned enrollment of 200 is above the median of 44 across 61 interventional studies indexed under Meniere Disease.

Browse Meniere Disease studies →

Lead sponsor

Sound Pharmaceuticals, Incorporated is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males/females, 18-75 years of age at the time of enrollment.
  • Diagnosis of probable or definite Meniere's Disease by AAO-HNS Amended 2015 Criteria.
  • At least two of three active symptoms (fluctuating hearing; tinnitus; aural fullness; vertigo or dizziness) of Meniere's disease, within 3 months of study enrollment.
  • Type A tympanogram at screening.
  • Air conduction thresholds ≤ 90 dB at all tested frequencies (250-8000 Hz) in both ears.
  • Subject is willing and able to provide and perform study procedures and assessments per protocol.
  • Reproductive requirements

Exclusion criteria

Exclusion Criteria:

  • Current, or within 60 days prior to study enrollment, use of IV or intratympanic ototoxic medications such as chemotherapy including cisplatin, carboplatin, or oxaliplatin; aminoglycoside antibiotics including gentamicin, amikacin, tobramycin, kanamycin, or streptomycin; or loop diuretics including furosemide.
  • History of otosclerosis or vestibular schwannoma.
  • History of significant middle ear or inner ear surgery in the affected ear.
  • Conductive hearing loss with air-bone gap ≥15 dB, otitis media, or mixed hearing loss.
  • Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, neurological, or psychiatric disease.
  • Current use or within 30 days prior to study enrollment systemic .
  • Current use or within 7 days prior to study enrollment intratympanic steroids.
  • or idiosyncratic reaction to compounds related to ebselen or .
  • Female patients who are pregnant or breastfeeding.
  • Participation in another drug or device study within 30 days prior to study consent.
  • Participant resides more than 100 miles from the study site.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Open Label

    Oral administration of SPI-1005 400 mg BID

    Drug: Ebselen

Interventions

  • Glutathione peroxidase mimetic

    Also known as: SPI-1005

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Safety and tolerability assessed based on adverse events

    Time frame: 180 and 360 days

07

Study locations

9 sites
08

References and documents

Publications

  • Kil J, Lobarinas E, Spankovich C, Griffiths SK, Antonelli PJ, Lynch ED, Le Prell CG. Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017 Sep 2;390(10098):969-979. doi: 10.1016/S0140-6736(17)31791-9. Epub 2017 Jul 14. PubMed 28716314 ↗
  • Kil J, Pierce C, Tran H, Gu R, Lynch ED. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res. 2007 Apr;226(1-2):44-51. doi: 10.1016/j.heares.2006.08.006. Epub 2006 Oct 6. PubMed 17030476 ↗
  • Kil J, Harruff EE, Longenecker RJ. Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hear Res. 2022 Jan;413:108209. doi: 10.1016/j.heares.2021.108209. Epub 2021 Feb 19. PubMed 33678494 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06859788
Lead sponsor
Sound Pharmaceuticals, Incorporated
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
Oct 29, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ebselen

Start the discussion